XM does not provide services to residents of the United States of America.
V
V

Vertex

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Vertex: Genomics PLC Announces New Extension And Expansion Of Drug Discovery Collaboration With Co

BRIEF-Vertex: Genomics PLC Announces New Extension And Expansion Of Drug Discovery Collaboration With Co July 16 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : GENOMICS PLC ANNOUNCES NEW EXTENSION AND EXPANSION OF DRUG DISCOVERY COLLABORATION WITH VERTEX GENOMICS PLC - THREE-YEAR EXTENSION OF COLLABORATION TO USE GENOMICS TO ACCELERATE DRUG DISCOV
V

Orum Therapeutics Anoounces Global, Multi-Target License, Option Agreement With Vertex For Use Of Orum's TPD Technology

BRIEF-Orum Therapeutics Anoounces Global, Multi-Target License, Option Agreement With Vertex For Use Of Orum's TPD Technology July 16 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : ORUM THERAPEUTICS-GLOBAL, MULTI-TARGET LICENSE, OPTION AGREEMENT WITH VERTEX FOR USE OF ORUM'S TPD² TECHNOLOGY TO DEVELOP DEGRADER-ANTIBODY CONJUGATES ORUM THERAPEUTIC
V

Vertex sues US over fertility support program for Casgevy gene editing therapy

UPDATE 2-Vertex sues US over fertility support program for Casgevy gene editing therapy Adds OIG response July 15 (Reuters) - Vertex Pharmaceuticals VRTX.O sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a fertility support program for patients who are prescribed its gene editing therapy Casgevy does not violate federal anti-kickback laws.
V

Vertex sues US over Casgevy gene editing therapy

Vertex sues US over Casgevy gene editing therapy July 15 (Reuters) - Vertex Phamaceuticals VRTX.O sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a fertility support program for patients who are prescribed its gene editing therapy Casgevy does not violate federal anti-kickback laws. The lawsuit was filed on the federal court in Washington, D.C.
V

Vertex Pharmaceuticals Says Vanza Triple Granted Priority Review With Prescription Drug User Fee Act

BRIEF-Vertex Pharmaceuticals Says Vanza Triple Granted Priority Review With Prescription Drug User Fee Act July 2 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : VERTEX ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR VANZACAFTOR/TEZACAFTOR/DEUTIVACAFTOR, A NEXT-IN-CLASS TRIPLE COMBINATION TREATMENT FOR CYSTIC FIBROSIS VERTEX PHARMACEUTICALS IN
V

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.